Zacharakis et al. recently described the case of a 49 year-old woman with ER+/HER2- metastatic BC refractory to multiple lines of chemotherapy, who exhibited a complete durable regression after ACT with TA-specific TILs in conjunction with IL-2 and an anti-PD1 agent (28). This evidence concerns the gene ERBB2 and breast cancer.